Keywords
perimenopause
estradiol
progesterone
prolactin
aldosterone
follicle-stimulating hormone
How to Cite
Abstract
The effect of sex hormone levels on the process of coronary heart disease was studied among 344 women from 41 to 59 years old in perimenopause. All patients were divided into two groups: the first group – 250 patients diagnosed with coronary heart disease, the second – 94 patients with no signs of this disease. The minimal observation period was 2 years, the maximal – 3 years 4 months. Sex hormone levels in blood serum were determined by ELISA. The perimenopause was determined according to the STRAW +10 classification. Survival analysis was conducted by evaluating a multicomponent point, including all of the above events. It was established that patients with coronary heart disease had significantly higher levels of progesterone than in patients without coronary heart disease, while the levels of estradiol, testosterone, follicle-stimulating hormone and aldosterone did not differ significantly in these groups. A more severe disease was observed among patients with prolactin level more than 211 mU/l, and among patients with a progesterone level exceeding 2,5 nmol/l. This statement is true only for women younger than 60 years, because patients of the older age group were not included in the research.
References
Zaw J.J., Howe P.R., Wong R.H. (2018). Postmenopausal health interventions: Time to move on from the Women’s Health Initiative? Ageing Research Reviews, vol. 48, pp.79–86, DOI: 10.1016/j.arr.2018.10.005.
Harlow S.D., Gass M., Hall J.E., Lobo R., Maki P., Rebar R.W., Villiers T.J. (2012). Executive summary of the stages of reproductive aging Workshop +10. Menopause, vol. 19 (4), pp. 387–395, DOI: 10.1097/gme.0b013e31824d8f40.
Losert W., Casals-Stenzel J., Buse M. (1985). Progestogens with antimineralocorticoid activity. Arzneimittelforschung, vol. 35 (2), pр. 459–471.
Anagnostis P., Paschou S.A., Katsiki N., Krikidis D., Lambrinoudaki I., Goulis D.G. (2019). Menopausal hormone therapy and cardiovascular risk: Where are we now? Current Vascular Pharmacology, vol. 17 (6), pp. 564–572, DOI: 10.2174/1570161116666180709095348.
Lieberman A., Curtis L. (2017). In defense of progesterone: a review of the literature. Altern. Ther. Health Med., vol. 23 (6), pp. 24–32.
Morrissy S., Xu B., Aguilar D., Zhang J., Chen Q.M. (2010). Inhibition of apoptosis by progesterone in cardiomyocytes. Aging Cell, vol. 9 (5), pp. 799–809, DOI: 10.1111/j.1474-9726.2010.00619.x.
Genazzani A.R., Mannella P., Simoncini T. (2007). Drosperinon and its antialdosteron proprieties. Clivacteric, vol. 10, suppl. 1, pp. 11–18.
Boschitsch E., Mayerhofer S., Magometschnigg D. (2010). Hypertension in women: The role of progesterone and aldosterone. Climacteric, vol. 13 (4), pp. 307–313, DOI: 10.3109/13697131003624649.
Funder J.W. (2007). Why are mineralocorticoid receptors so nonselective? Current Hypertension Reports, vol. 9 (2), pp. 112–116, DOI: 10.1007/s11906-007-0020-8.
Osadnik T., Pawlas N., Osadnik K., Bujak K., Góral M., Lejawa M. et al. (2019). High progesterone levels are associated with family history of premature coronary artery disease in young healthy adult men. PLoS One, vol. 14 (4), e0215302, DOI: 10.1371/journal.pone.0215302.
Elgayar H., Abu-Shady M., Zaki I., Abdelsalam M., Elsherbeny A. (2011). Study of serum prolactin and cardiovascular risk in patients with type 2 diabetes mellitus. Birmingham, UK 11 April 2011 – 14 April 2011. Endocrine: Abstracts, vol. 25, pp. 157.
Serri O., Li L., Mamputu J., Beauchamp M., Maingrette F., Renier G. (2006). The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clinical Endocrinology, vol. 64 (4), pp. 366–370, DOI: 10.1111/j.1365-2265.2006.02469.x.
Jiang X., Li C., He D., Mao Z., Liu D., Fan X. et al. (2013). Increased carotid intima media thickness is associated with prolactin levels in subjects with untreated prolactinoma: A pilot study. Pituitary, vol. 17 (3), pp. 232–239, DOI: 10.1007/s11102-013-0495-z.
Therkelsen K.E., Abraham T.M., Pedley A., Massaro J.M., Sutherland P., Hoffmann U., Fox C.S. (2016). Association between prolactin and incidence of cardiovascular risk factors in the Framingham Heart Study. Journal of the American Heart Association, vol. 5 (2), DOI: 10.1161/jaha.115.002640.